US FDA accepts for priority review for Sanofi’s sBLA for Tzield for young children with stage 2 type 1 diabetes: Paris Tuesday, January 6, 2026, 12:00 Hrs [IST] The US Food and ...

Quitting added sugar for just 14 days can lead to noticeable changes in energy levels, cravings, insulin response and gut ...

The global aerosol delivery devices market size was US$ 14.5 billion in 2021. The global aerosol delivery devices market is forecast to grow to US$ 21.1 billion by 2030 by growing at a compound annual ...

The sBLA is supported by 1-year interim data from the ongoing phase 4 PETITE-T1D study, which included 23 children less than 8 years of age with stage 2 T1D.

Metformin for weight loss was prescribed to Jelly Roll by nurse practitioner Danese Raxroad to reduce triglycerides and improve insulin signaling during his transformation ...

Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes ...

Sanofi has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab-mzwv) to expand the ...

Scientists identify key gene SMOC1 linked to Type 2 diabetes. Discovery could lead to advanced treatments targeting the root ...

Sanofi could be months away from wider US approval for Tzield, its first-in-class drug for delaying the progression of type 1 ...

Sanofi’s Tzield has been accepted for priority review by the U.S. Food and Drug Administration to expand its use to children aged one year and older with stage 2 type 1 diabetes. The submission is ...

New AIIMS-ICMR Study Finds Heart Problems Behind Sudden Young Deaths Sudden deaths in seemingly healthy young adults are ...